Spark Therapeutics, Inc. (ONCE) Downgraded to Sell at ValuEngine

Spark Therapeutics, Inc. (NASDAQ:ONCE) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

A number of other research firms also recently weighed in on ONCE. Royal Bank Of Canada restated a “buy” rating on shares of Spark Therapeutics in a research report on Wednesday, October 25th. Cantor Fitzgerald restated a “buy” rating on shares of Spark Therapeutics in a research report on Friday, August 25th. Raymond James Financial, Inc. started coverage on Spark Therapeutics in a research report on Thursday, October 12th. They issued an “outperform” rating and a $96.00 target price for the company. Chardan Capital upgraded Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $60.00 to $100.00 in a research report on Tuesday, August 8th. Finally, BidaskClub upgraded Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and eighteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $90.36.

Spark Therapeutics (NASDAQ ONCE) opened at $72.65 on Tuesday. Spark Therapeutics has a fifty-two week low of $47.03 and a fifty-two week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same period last year, the company earned ($1.07) earnings per share. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. equities research analysts anticipate that Spark Therapeutics will post -7.62 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/11/14/spark-therapeutics-inc-once-downgraded-to-sell-at-valuengine.html.

In other news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $84.63, for a total value of $84,630,000.00. Following the transaction, the director now directly owns 3,928,707 shares of the company’s stock, valued at $332,486,473.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Barge Joseph La sold 5,500 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $71.44, for a total transaction of $392,920.00. Following the completion of the transaction, the insider now directly owns 8,146 shares in the company, valued at $581,950.24. The disclosure for this sale can be found here. Insiders sold 1,099,659 shares of company stock worth $92,457,658 over the last ninety days. 7.30% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of ONCE. Ameritas Investment Partners Inc. increased its position in Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Spark Therapeutics during the second quarter worth $143,000. BNP Paribas Arbitrage SA increased its position in Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the last quarter. Pacad Investment Ltd. increased its position in Spark Therapeutics by 75.0% during the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after buying an additional 1,500 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Spark Therapeutics during the third quarter worth $225,000. 77.94% of the stock is currently owned by hedge funds and other institutional investors.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply